These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22875640)

  • 1. Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS.
    Saito M; Matsuzaki M; Sakuma T; Katagata N; Watanabe F; Yamaguchi Y; Schetter AJ; Takenoshita S; Nomizu T
    Breast Cancer; 2014 Mar; 21(2):140-5. PubMed ID: 22875640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition.
    Obdeijn IM; Loo CE; Rijnsburger AJ; Wasser MN; Bergers E; Kok T; Klijn JG; Boetes C
    Breast Cancer Res Treat; 2010 Jan; 119(2):399-407. PubMed ID: 19876732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    van der Groep P; van Diest PJ; Smolders YH; Ausems MG; van der Luijt RB; Menko FH; Bart J; de Vries EG; van der Wall E
    PLoS One; 2013; 8(2):e56055. PubMed ID: 23409121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and imaging features of ductal carcinoma in situ in BRCA1/2 mutation carriers.
    Seki A; Tsunoda H; Takei J; Suzuki M; Kanomata N; Yamauchi H
    Breast Dis; 2023; 42(1):5-15. PubMed ID: 36806499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of radioactive iodine-125 seed localization in patients with non-palpable breast cancer: a comparison with the radioguided occult lesion localization with 99m technetium.
    van der Noordaa ME; Pengel KE; Groen E; van Werkhoven E; Rutgers EJ; Loo CE; Vogel W; Vrancken Peeters MJ
    Eur J Surg Oncol; 2015 Apr; 41(4):553-8. PubMed ID: 25707349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among
    Faermann R; Friedman E; Kaidar-Person O; Weidenfeld J; Brodsky M; Shalmon A; Halshtok Neiman O; Gotlieb M; Yagil Y; Samoocha D; Madorsky Feldman D; Sklair-Levy M
    Breast J; 2022; 2022():4317693. PubMed ID: 36349178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
    Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
    J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
    Noh JM; Choi DH; Nam SJ; Lee JE; Kim JW; Kim SW; Kang E; Lee MH; Ahn SH; Kim KS; Park SK; Haffty BG;
    Breast Cancer Res Treat; 2012 Jan; 131(1):217-22. PubMed ID: 21847643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.
    Elsayegh N; Kuerer HM; Lin H; Gutierrez Barrera AM; Jackson M; Muse KI; Litton JK; Albarracin C; Afrough A; Hortobagyi GN; Arun BK
    Ann Surg Oncol; 2014 Oct; 21(11):3466-72. PubMed ID: 24796968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
    Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
    Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?
    Passaperuma K; Warner E; Hill KA; Gunasekara A; Yaffe MJ
    J Clin Oncol; 2010 Aug; 28(23):3779-83. PubMed ID: 20625126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
    Nomizu T; Matsuzaki M; Katagata N; Kobayashi Y; Sakuma T; Monma T; Saito M; Watanabe F; Midorikawa S; Yamaguchi Y
    Breast Cancer; 2015 Sep; 22(5):557-61. PubMed ID: 23242612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer.
    Panchal S; Shachar O; O'Malley F; Crystal P; Escallon J; Crook J; Bane A; Bordeleau L
    Nat Rev Clin Oncol; 2009 Oct; 6(10):604-7. PubMed ID: 19787003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
    Claus EB; Petruzella S; Matloff E; Carter D
    JAMA; 2005 Feb; 293(8):964-9. PubMed ID: 15728167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.